Voyager Therapeutics (NASDAQ:VYGR) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Voyager Therapeutics (NASDAQ:VYGR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Voyager Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia [Yahoo! Finance]
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia